Precigen, a biotechnology company headquartered in Germantown, Maryland, focuses on synthetic biology technologies and develops therapies for urgent diseases. Founded in 2013, it operates through Biopharmaceuticals and Exemplar segments.
Precigen (PGEN) reported a negative EPS surprise in its most recent quarterly earnings. For the most recent quarter, Precigen's actual EPS was -$0.09, missing the estimate of -$0.08 per share, resulting in a -6.76% surprise.
📡️ Health Care
Earnings Surprise
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
